Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.
Authors
Elise A. Chong (ORCID: https://orcid.org/0000-0001-8895-1625)
Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.
Elise A. Chong, David Bernasconi, Iris Isufi, Samantha Jaglowski et al.
Journal
Journal of Clinical Oncology
Topics
CAR-T cell therapy research
article
Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.
Elise A. Chong, David Bernasconi, Iris Isufi, Samantha Jaglowski, Matthew A. Lunning, L Wang, K. Patel, Bradley Hunter, Debasmita Roy, Jason Romancik, Uttam Rao, J Huang, Michael Wang, Amitkumar Mehta, Lizamarie Bachier, Taylor Brooks
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 44(16_suppl)
Institutions
Northside Hospital (US), Intermountain Healthcare (US), Cleveland Clinic (US), Hackensack University Medical Center (US), The University of Texas MD Anderson Cancer Center (US), University of Washington (US), Medical College of Wisconsin (US), LDS Hospital (US), University of Alabama at Birmingham (US), Yale University (US), Fred Hutch Cancer Center (US), Bristol-Myers Squibb (United States) (US), St David's Medical Center (US), Bristol-Myers Squibb (Switzerland) (CH), University of Nebraska Medical Center (US), University of Pennsylvania (US)